Facebook Linkedin RSS Twitter Youtube
Home 2024

Respiratory syncytial virus

StockWatch: Moderna’s $1.1B R&D Cut, Profitability Delay Jolt Investors
Drug Discovery

StockWatch: Moderna’s $1.1B R&D Cut, Profitability Delay Jolt Investors

Increasing Vaccine Efficacy with Novel Adjuvants
Bioprocessing

Increasing Vaccine Efficacy with Novel Adjuvants

StockWatch: Analysts Mixed on Moderna Despite $750M Financing, Vaccine Updates
Drug Discovery

StockWatch: Analysts Mixed on Moderna Despite $750M Financing, Vaccine Updates

RNA Medicines Address Stability and Deliverability Challenges
Insights

RNA Medicines Address Stability and Deliverability Challenges

Decades of mRNA Research Come to Fruition
Coronavirus

Decades of mRNA Research Come to Fruition

SARS-CoV-2 Aerosols Detected Indoors, in Minutes, by Air Monitor
Infectious Diseases

SARS-CoV-2 Aerosols Detected Indoors, in Minutes, by Air Monitor

First RSV Vaccine Approved by FDA
Infectious Diseases

First RSV Vaccine Approved by FDA

Multiple Vaccine Technologies Converge on Respiratory Syncytial Virus
Insights

Multiple Vaccine Technologies Converge on Respiratory Syncytial Virus

Tripledemic Rouses Vaccine Developers and Variant Trackers
Drug Discovery

Tripledemic Rouses Vaccine Developers and Variant Trackers

Bob Langer Answers Your Webinar Questions
Insights

Bob Langer Answers Your Webinar Questions

123...6Page 1 of 6
Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.